Evaluation of recombinant human prourokinase for acute pulmonary embolism: A phase 2, randomized clinical trial - PubMed
6 hours ago
- #thrombolytic therapy
- #pulmonary embolism
- #clinical trial
- Recombinant human prourokinase (rhPro-UK) was evaluated against alteplase (rt-PA) in a phase 2 trial for acute pulmonary embolism.
- Patients received intravenous rhPro-UK (40 mg or 50 mg) or rt-PA, with primary outcome being systolic pulmonary artery pressure change at 24 hours.
- All groups showed reduced systolic pulmonary artery pressure, with improvements sustained through 30 days, indicating comparable hemodynamic improvement.
- Non-major bleeding events were numerically lower in rhPro-UK groups (40 mg: 63.9%, 50 mg: 55.6%) compared to rt-PA group (82.9%).
- Two deaths occurred, one in the 40 mg rhPro-UK group and one in the rt-PA group.
- The trial was funded by Tasly Biopharmaceuticals Co., Ltd., with data supporting further investigation of rhPro-UK's safety and efficacy.